🇺🇸 FDA
Patent

US 10550391

Organic compositions to treat beta-ENaC-related diseases

granted A61KA61K31/713A61P

Quick answer

US patent 10550391 (Organic compositions to treat beta-ENaC-related diseases) held by Arrowhead Pharmaceuticals, Inc. expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/713, A61P, A61P1/00, A61P1/18